Who are Azathioprine OR Mesalazine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azathioprine-or-mesalazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Azathioprine OR Mesalazine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azathioprine OR Mesalazine (Azathioprine OR Mesalazine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant and anti-inflammatory combination. Area: Gastroenterology / Immunology.

phase 3 Immunosuppressant and anti-inflammatory combination Purine metabolism (azathioprine); NF-κB pathway (mesalazine) Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Azathioprine OR Mesalazine (Azathioprine OR Mesalazine) — Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. This is a combination therapy study comparing azathioprine (an immunosuppressant) and mesalazine (an anti-inflammatory) for inflammatory bowel disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azathioprine OR Mesalazine TARGET	Azathioprine OR Mesalazine	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	phase 3	Immunosuppressant and anti-inflammatory combination	Purine metabolism (azathioprine); NF-κB pathway (mesalazine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant and anti-inflammatory combination class)

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azathioprine OR Mesalazine — Competitive Intelligence Brief. https://druglandscape.com/ci/azathioprine-or-mesalazine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab